F2G LTD: F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
Olorofim is currently in Phase 2b development for the treatment of life-threatening fungal infections